XML 56 R2.htm IDEA: XBRL DOCUMENT v3.20.1
Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2020
Dec. 31, 2019
Current assets:    
Cash and cash equivalents $ 15,260 $ 8,377
Short-term investments – available for sale 253,901 267,261
Prepaid clinical trial and preclinical study costs 6,738 7,458
Prepaid expenses and other current assets 547 405
Total current assets 276,446 283,501
Right-of-use assets 530 598
Deferred public offering and other financing costs 99 128
Deposits 29 29
Total assets 277,104 284,256
Current liabilities:    
Accounts payable 3,098 2,431
Other accrued liabilities 5,135 4,044
Lease liability, current 309 302
Total current liabilities 8,542 6,777
Lease liability, net of current portion 279 360
Total long-term liabilities 279 360
Total liabilities 8,821 7,137
Commitments and contingencies (Note 8)
Stockholders’ equity:    
Preferred stock, $0.00001 par value: 10,000,000 shares authorized at March 31, 2020 and December 31, 2019; no shares issued and outstanding at March 31, 2020 and December 31, 2019
Common stock, $0.00001 par value: 300,000,000 shares authorized at March 31, 2020 and December 31, 2019; 72,562,863, and 72,413,602 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively 1 1
Additional paid-in capital 407,478 405,803
Accumulated deficit (138,384) (128,697)
Accumulated other comprehensive income (loss) (812) 12
Total stockholders’ equity 268,283 277,119
Total liabilities and stockholders’ equity $ 277,104 $ 284,256